PCSA Insider Trading

Insider Ownership Percentage: 13.00%
Insider Buying (Last 12 Months): $105,895.00
Insider Selling (Last 12 Months): $0.00

Processa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Processa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Processa Pharmaceuticals Share Price & Price History

Current Price: $0.81
Price Change: Price Decrease of -0.057 (-6.59%)
As of 01/17/2025 04:59 PM ET

This chart shows the closing price history over time for PCSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$0.81Closing price on 01/17/25:

SEC Filings (Institutional Ownership Changes) for Processa Pharmaceuticals (NASDAQ:PCSA)

91.93% of Processa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PCSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$50k$0$50kTotal InflowsTotal Outflows
Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
Read More on Processa Pharmaceuticals

Today's Range

Now: $0.81
Low: $0.80
High: $0.84

50 Day Range

MA: $0.98
Low: $0.83
High: $1.33

52 Week Range

Now: $0.81
Low: $0.80
High: $7.14

Volume

55,197 shs

Average Volume

63,718 shs

Market Capitalization

$2.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of Processa Pharmaceuticals?

Processa Pharmaceuticals' top insider investors include:
  1. David Young (Insider)
  2. Justin W Yorke (Director)
  3. Patrick Lin (Insider)
  4. David Young (CEO)
  5. George K Ng (CEO)
Learn More about top insider investors at Processa Pharmaceuticals.